Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
-
Publication number: 20150118267Abstract: A method for enhancing the immune system or for treating an infectious disease, the method includes administering to a subject in need thereof an effective amount of theaflavins, analogs thereof, or prodrugs thereof, or includes administering to a subject a composition comprising a physiologically acceptable carrier and an effective amount of an extract of tea.Type: ApplicationFiled: October 29, 2014Publication date: April 30, 2015Inventors: Shiming Li, Xueyin Ren, Jianhong Liu
-
Publication number: 20150119418Abstract: Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C1-C3 linear alkylene group, in which one methylene group is optionally substituted with O or S; n represents an integer of from 3 to 5; X1 and X2 each independently represent CH or N; W1 and W2 each independently represent a carboxyl group or a tetrazolyl group; V represents a C1-C8 linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; and R represents a substituted phenyl group, for example.Type: ApplicationFiled: April 15, 2013Publication date: April 30, 2015Applicant: TOA EIYO LTD.Inventors: Kazuhiro Uemoto, Yoshimichi Sato, Naoki Okada, Emiko Iimori, Masayuki Kageyama
-
Publication number: 20150119457Abstract: The invention is referring to an essential oil from lemon peel useful as growth promoter in poultry, such composition comprises at least 16.84 to 46.12% of D-Limonene; 5.67 to 19.86% of y-Terpinene; 4.27 to 12.13% of Terpinolene; 4.60 to 14.75% of p-Ment-1-en-8-ol; among other components. The invention also refers to a poultry food supplement, which comprises 1 kg per metric ton of food from such composition of essential oil.Type: ApplicationFiled: November 9, 2012Publication date: April 30, 2015Inventors: Rosario Elena Rojas Duran, Carlos Martin Shiva Ramayoni, Juan Kalinowski Echegaray, Christian Alejandro Villavicencio Gallarday, Michel Henri Auguste Sauvain
-
Publication number: 20150119348Abstract: Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of Rhodiola rosea are structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are useful in preventing and treating diseases and disorders associated with aberrant Cdk5 activities, such as acute and/or chronic pain, neuropathic pain, diabetes mellitus, cancer, neurodegenerative diseases and neuropathological disorders.Type: ApplicationFiled: December 30, 2014Publication date: April 30, 2015Inventors: Nancy Yuk-Yu IP, Fanny Chui-Fun IP, Wing Yu FU, Guangmiao FU
-
Patent number: 9018249Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).Type: GrantFiled: September 12, 2012Date of Patent: April 28, 2015Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S. Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
-
Patent number: 9018247Abstract: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: GrantFiled: June 1, 2011Date of Patent: April 28, 2015Assignees: Children's Hospital Medical Center, Australian Health & Nutrition Association LimitedInventors: Kenneth David Reginald Setchell, Sidney John Cole
-
Patent number: 9018248Abstract: The present disclosure relates to fatty acid derivatives of green tea catechins including epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC), epigallocatechin gallate (EGCG) and their epimers (e.g., catechin, catechin gallate, gallocatechin, gallocatechin gallate) or their mixtures and/or green tea extracts.Type: GrantFiled: April 8, 2011Date of Patent: April 28, 2015Assignee: Genesis Group Inc.Inventors: Fereidoon Shahidi, Ying Zhong
-
Publication number: 20150111961Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Kunihiro KAIHATSU, Shuichi MORI, Tomo DAIDOJI, Nobuo KATO, Shinya MIYAKE
-
Publication number: 20150111916Abstract: This invention relates to the use of a composition comprising opioid/Toll-like receptor 4 (TLR4) antagonists and dextro enantiomers thereof for the treatment of pain, where the opioid antagonists treat pain by blocking TLR4. More preferably, the dextro opioid/TLR4 antagonist enantiomer treats pain by blocking TLR4 while not affecting the opioid receptors and therefore avoiding adverse effects associated with blocking the opioid receptors. Examples of opioid antagonist and their dextro enantiomers include naltrexone, naloxone and nalmefene, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.Type: ApplicationFiled: March 27, 2013Publication date: April 23, 2015Inventor: Annette Channa Toledano
-
Patent number: 9012495Abstract: The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described.Type: GrantFiled: December 11, 2009Date of Patent: April 21, 2015Assignee: Axcentua Pharmaceuticals ABInventors: Anders Berkenstam, Stefan Rehnmark, Michael-Robin Witt, Keith Lorimer, Stephen Watt
-
Patent number: 9011943Abstract: The disclosure relates to the discovery that fractionated coconut oil is effective for alleviating existing skin disorders when applied topically to the skin of a person afflicted with such a disorder. The disclosure further relates to the discovery that fractionated coconut oil can be used to prevent or inhibit onset of a skin disorder or to reduce the severity of a skin disorder when administered prophylactically to the skin of a person. A cromolyn compound, a corticosteroid, or both, can be included in the composition.Type: GrantFiled: December 14, 2009Date of Patent: April 21, 2015Assignee: Skin Evolution LLCInventor: Betty Bellman
-
Publication number: 20150105338Abstract: The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C1 or C2 and wherein for C2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more H or OH, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow.Type: ApplicationFiled: July 17, 2014Publication date: April 16, 2015Applicant: PROVEXIS NATURAL PRODUCTS LIMITEDInventor: Niamh O'Kennedy
-
Patent number: 9005664Abstract: The present invention is directed to co-assembled nanoparticle composition comprising denatured ?-lactoglobulin and at least one nutraceutical compound, specifically polyphenols, such as EGCG, compositions comprising same and methods of preparing thereof.Type: GrantFiled: October 17, 2011Date of Patent: April 14, 2015Assignee: Technion Research and Development Foundation Ltd.Inventors: Yoav D. Livney, Avi Shpigelman
-
Publication number: 20150099802Abstract: A method for treating a tumor with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative, a method for suppressing the growth of a tumor cell with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH), which comprises contacting said tumor cell with an effective amount of a fatty acid derivative, and a method for identifying a subject who would be responsive to a fatty acid derivative, comprising, (i) obtaining a biological sample from said subject; and (ii) measuring 15-hydroxyprostaglandin dehydrogenase (15-PGDH) level are provided.Type: ApplicationFiled: October 1, 2014Publication date: April 9, 2015Applicant: SUCAMPO AGInventors: Ryuji UENO, Sachiko KUNO
-
Patent number: 9000033Abstract: Disclosed is a cosmetic composition comprising prenylated isoflavonoid and a carrier, wherein the prenylated isoflavonoid is from about 0.0000001% to about 10%, preferably from 0.00001% to 1%, most preferably from 0.01% to 1%, by weight, based on the total weight of the composition. The active agent prenylated isoflavonoid induces a statistically significant upregulation of collagen 1A1 and elastin genes in normal human dermal fibroblasts. The composition is effective to stimulate the production of collagen and elastin and improve the appearance and condition of the skin.Type: GrantFiled: July 30, 2009Date of Patent: April 7, 2015Assignee: Arch Personal Care Products, L.P.Inventor: James V Gruber
-
Publication number: 20150094364Abstract: A method for treating alcoholic liver diseases or for preventing or ameliorating at least one of the symptoms of an alcoholic liver disease, the method includes administering to a subject in need thereof an effective amount of theaflavin, an analog thereof, or a prodrug thereof, or includes administering to the subject a composition comprising an extract of tea and a physiologically acceptable carrier.Type: ApplicationFiled: September 30, 2014Publication date: April 2, 2015Inventor: Dongning Li
-
Publication number: 20150094365Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael KROHN, Holger ZINKE
-
Patent number: 8993619Abstract: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.Type: GrantFiled: April 26, 2013Date of Patent: March 31, 2015Assignee: Novartis AGInventors: Sejal Patel, Justin Mao, Qian Liu, Rui Zheng, Tyler Harrison, Rohit Duvadie, Xin Chen, Frederic Zecri, Jay Larrow, Xuchun Zheng, Yizong Zhou, Jiong Ye, Yiping Ding, Yu Gai
-
Patent number: 8993618Abstract: New pharmaceutical compositions extracted from Ferula assa-foetida are confirmed to effectively treat influenza A (H1N1) virus. The extraction method of the new pharmaceutical compositions mainly includes steps of: (a) extracting F. assa-foetida with methanol to obtain a crude extract; (b) fractioning the crude extract with n-hexane-methanol to obtain a methanol extract; (c) fractioning the methanol extract with chloroform-water to obtain a chloroform extract; and (d) chromatographing the chloroform extract to obtain the pharmaceutical compositions, which can be further fractioned and chromatographed to obtain various sesquiterpene coumarins.Type: GrantFiled: July 21, 2014Date of Patent: March 31, 2015Assignee: Kaohsiung Medical UniversityInventors: Yang-Chang Wu, Fang-Rong Chang, Lien-Chai Chiang
-
Publication number: 20150087699Abstract: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.Type: ApplicationFiled: May 3, 2013Publication date: March 26, 2015Inventors: Jayaraman V. Raman, Swaroop K. Vakkalanka
-
Publication number: 20150087698Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone, and from which formulated products may be prepared.Type: ApplicationFiled: September 24, 2013Publication date: March 26, 2015Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: JOHN CHARLES FISHER, KEITH W. HUTCHENSON, SCOTT CHRISTOPHER JACKSON, LEO ERNEST MANZER, MARK A. SCIALDONE, MAYIS SEAPAN
-
Patent number: 8987223Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.Type: GrantFiled: May 14, 2012Date of Patent: March 24, 2015Assignee: Oncogenex Technologies Inc.Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
-
Patent number: 8987262Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.Type: GrantFiled: November 16, 2012Date of Patent: March 24, 2015Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de BordeauxInventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
-
Publication number: 20150080461Abstract: The present invention relates to a composition having antiviral activity for prophylaxis or treatment of flavivirus infection or a disease resulting therefrom in humans or animals, characterised in that the composition comprises quercetin, or analogues, or derivatives thereof. The composition may further comprise a pharmaceutically acceptable carrier. The antiviral activity may include inhibition of virus attachment to host cells and inhibition of intracellular virus replication. The flavivirus may comprise dengue virus type-1, dengue virus type-2, dengue virus type-3, and dengue virus type-4.Type: ApplicationFiled: January 31, 2013Publication date: March 19, 2015Inventor: Sazaly Abu Bakar
-
Publication number: 20150080462Abstract: The present invention features methods for treating or preventing conditions, diseases, or disorders related to oxidative stress. In one embodiment, the method increases Nrf2 biological activity or expression. In particular, the invention provides for the treatment or prevention of diseases relating to oxidative stress including emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia and neurodegenerative disorders, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia, cognitive deficits and neurodegenerative disorders.Type: ApplicationFiled: August 4, 2014Publication date: March 19, 2015Inventors: Shyam Biswal, Sylvain Dore, Rajesh Kumar Thimmulappa, Tirumalai Rangasamy, Yoshihito Sakata, Zahoor Ahmad Shah, Hean Zhuang, Anju Singh
-
Publication number: 20150080328Abstract: The present invention relates to compounds and compositions and their application as pharmaceuticals for treating, preventing, or reversing injury to skeletal or cardiac muscles, for treating or preventing diseases relating to the structure and function of skeletal or cardiac muscle, and for inducing regeneration or restructuring of skeletal or cardiac muscle as a means of treating diseases relating to abnormalities in skeletal or cardiac muscle structure and function in a human or animal subject.Type: ApplicationFiled: March 22, 2013Publication date: March 19, 2015Inventors: Francisco Villarreal, George F. Schreiner, Guillermo Ceballos
-
Publication number: 20150079107Abstract: Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.Type: ApplicationFiled: April 26, 2013Publication date: March 19, 2015Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Anna I. Mandinova, Sam W. Lee, Victor A. Neel
-
Publication number: 20150073044Abstract: Long-chain carboxychromanol compounds useful for treating conditions associated with the need to inhibit cyclooxygenase-1, cyclooxygenase-2, and/or 5-lipoxygenase, and pharmaceutical formulations containing the compounds are provided herein.Type: ApplicationFiled: August 29, 2014Publication date: March 12, 2015Inventor: QING JIANG
-
Publication number: 20150073043Abstract: A method for the treatment and/or the prevention of a disease or a symptom related to dysfunction of regulatory T cell immunomodulation includes administering to a subject in need thereof compositions that regulate regulatory T cell immunomodulatory function, in which the compositions may be prepared by contacting starting materials with phosphorylation pathway-related factors, the agonists or the antagonists thereof. The phosphorylation pathway-related factors are selected from: proto-oncogene protein PIM1 and the coding sequence thereof. The regulation is achieved by regulating the activity of regulators of regulatory T cells selected from the group: FOXP3, IL-2, GITR, CTLA4, and a combination thereof.Type: ApplicationFiled: January 21, 2013Publication date: March 12, 2015Inventors: Bin Li, Zhiyuan Li, Fang Lin, Zhimei Gao, Zuojia Chen, Andy Tsun, Kongchen Li
-
Publication number: 20150072012Abstract: A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.Type: ApplicationFiled: November 13, 2014Publication date: March 12, 2015Inventors: Ravichandran SRIPATHY, Venkata Narasimha Siva Rama Raju MANDAPATI, Gopaal AJAY, Nirvanashetty SOMASHEKARA, Ramchand Nanappan CHANIYILPARAMPU, Rama Raju GOKARAJU, Ganga Raju GOKARAJU, Kiran BHUPATHIRAJU, Dwarakanath ANJANA
-
Publication number: 20150072953Abstract: The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of modulating joint inflammation, joint pain, joint stiffness, cartilage degradation, or improving mobility, range of motion, flexibility, joint physical function, or any combination thereof. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other joint management agents, such as non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, glucosamine compounds, neuropathic pain relief agents, or the like.Type: ApplicationFiled: June 16, 2014Publication date: March 12, 2015Inventors: Lidia Alfaro Brownell, Min Chu, Mei-Feng Hong, Eu-Jin Hyun, Qi Jia, Ping Jiao, Hyun-Jin Kim, Mi-Ran Kim, Tae-Woo Kim, Bo-Su Lee, Young-Chul Lee, Breanna Moore, Jeong-Bum Nam, Mi-Sun Oh, Mi-Hye Park, Mesfin Yimam, Qian Zhang
-
Publication number: 20150072958Abstract: Various embodiments of the present invention relate to, among other things, compounds and methods of using those compounds to treat an HIV infection. The compounds of the various embodiments of the present invention provide, among other things, therapeutic agents having enhanced penetration capability across the blood-brain barrier, such that they can enter the CNS to treat an HIV-1 infection in the CNS.Type: ApplicationFiled: September 10, 2014Publication date: March 12, 2015Inventors: Arun K. Ghosh, Hiroaki Mitsuya, Sofiya Yashchuk
-
Patent number: 8975236Abstract: There is disclosed a dietary supplement composition of alkaloids and flavonoids extracted from citrus fruits that exhibits lipolytic and thermogenic activity and increases RMR, while at the same time exhibiting no negative side effects such as increase in blood pressure or heart rate. The composition essentially comprises two components: (A) the protoalkaloids synephrine, tyramine, N-methyltyramine, hordenine and octopamine; and (B) at least one of hesperidin, naringin and mixtures thereof.Type: GrantFiled: June 13, 2011Date of Patent: March 10, 2015Inventors: Sidney J. Stohs, Howard Miller
-
Publication number: 20150064261Abstract: A multiparticulate dosage form includes a plurality of individual spheroidal enteric coated particulates having (a) a diameter of 0.1 to 2.5 mm; (b) a solid core containing an effective amount of a combination of an L-menthol source and a terpene-based essential oil; (c) a continuous proteinaceous subcoating over the core; and (d) an enteric coating over the subcoating. The multiparticulate dosage form can be used to treat gastrointestinal disorders.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Syed M. Shah, Fred Hassan, Daniel Hassan, Sarah Hassan
-
Publication number: 20150065438Abstract: A prepackaged sterile syringe or bottle with various concentrations of tissue and organ biologically stimulating reagents i.e., dextrose, various anthocyanins, anthocyanidins and/or their various metabolites (i.e., protocatechuic acid) as the base, can be used as a product and service not otherwise available to those practicing prolotherapy. A selected bioactive agent could be added to enhance the treatment effectiveness. The prepackaged sterile syringe or bottle can be produced in standardized concentrations of reagents and can be produced in a regulated facility to meet all the government standards of oversight necessary to insure a safe sterile product of uniform nature. The prepackaged sterile syringe or bottle provides cost savings as well as enhanced quality control, time and labor efficiency at the treatment sites.Type: ApplicationFiled: August 29, 2013Publication date: March 5, 2015Inventor: Lanny Leo Johnson
-
Publication number: 20150065566Abstract: The present invention provides methods for preventing colon cancer by administering, to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to prevent colon cancer, which composition inhibits COX-2. The present invention also provides methods for treating inflammation locally in the intestines comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat inflammation. In one embodiment, the polymeric proanthocyanidin compound is crofelemer. The present invention in alternative embodiments provides methods for treating pain locally in the intestines and treating inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, as well as for treating familial adenomatous polyposis (FAP).Type: ApplicationFiled: September 3, 2014Publication date: March 5, 2015Inventor: Barry D. Quart
-
Publication number: 20150065513Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Applicant: PFIZER INC.Inventor: Vincent Mascitti
-
Publication number: 20150057342Abstract: Provided are oral pharmaceutical compositions comprising sustained release or a combination of sustained and immediate release formulation of cannabinoids, a process for their preparation and methods of use thereof.Type: ApplicationFiled: July 31, 2014Publication date: February 26, 2015Inventors: Zohar KOREN, Eyal BALLAN, Itamar BOROCHOV, Shay Avraham SARID
-
Publication number: 20150056166Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.Type: ApplicationFiled: March 22, 2013Publication date: February 26, 2015Inventors: Thomas Pietschmann, Sibylle Haid, Juliane Gentzsch, Christina Grethe, Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Mourad Elhabiri, Xavier Benlloch-Martin
-
Patent number: 8962678Abstract: Provision of a drug, a quasi-drug, and a food or beverage, which are effective for senescence inhibition, mitochondrial function improvement, muscle dysfunction inhibition, muscular atrophy inhibition, prevention of a bedridden state, muscle senescence inhibition, or motor function improvement. A senescence inhibitor, a mitochondrial function-improving agent, a muscle dysfunction inhibitor, a muscular atrophy inhibitor, and an agent for preventing a bedridden state, containing a catechin as an effective ingredient. A muscle senescence inhibitor and a motor function-improving agent, containing a catechin and an amino acid as effective ingredients.Type: GrantFiled: June 29, 2007Date of Patent: February 24, 2015Assignee: Kao CorporationInventors: Noriyasu Ota, Satoshi Haramizu, Takatoshi Murase
-
Patent number: 8962017Abstract: A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.Type: GrantFiled: November 23, 2009Date of Patent: February 24, 2015Assignee: Jiangsu UniversityInventors: Ximing Xu, Jiangnan Yu, Shanshan Tong, Yuan Zhu, Xia Cao
-
Patent number: 8962679Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: GrantFiled: July 8, 2011Date of Patent: February 24, 2015Assignees: The Administrators of the Tulane Educational Fund, Xavier University of LouisianaInventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
-
Publication number: 20150050357Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.Type: ApplicationFiled: October 27, 2014Publication date: February 19, 2015Applicant: Humanetics CorporationInventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
-
Publication number: 20150051273Abstract: The invention relates to the use of delphinidin or salts thereof, which is aimed at bacteria selected from the group comprising antibiotic-resistant Staphylococcus aureus and antibiotic-sensitive Staphylococcus aureus and at least partially neutralizes said bacteria, and methods for treating objects with delphinidin or salts thereof.Type: ApplicationFiled: March 28, 2013Publication date: February 19, 2015Inventors: Norbert Roewer, Jens Broscheit
-
Publication number: 20150051272Abstract: The invention discloses the uses of hydroxyl polymethoxylflavones and derivative thereof that are relative to inhibit adipogenesis and lower lipid accumulation, wherein the hydroxyl polymethoxylflavones is obtained from the peels of Citrus genus plants. Therefore, the hydroxyl polymethoxylflavones that of a therapeutically effective amount not only can be a medical compound for treatment obesity or fatty liver, but also can be a food element.Type: ApplicationFiled: January 28, 2014Publication date: February 19, 2015Applicants: Greenyn Biotechnology Co., LtdInventors: Min-Hsiung PAN, Chia-Li WU
-
Publication number: 20150051270Abstract: A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein either Q1, CR6a and optionally R6b together form a cyclic moiety wherein: Q1 is selected from C1-2 alkylene, C1-2 alkenylene, OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo; R6a is a single bond and R6b is H; or R6a and R6b together form a double bond; and Q2 and Q3 are independently selected from H, R1 and R2; or Q2 and Q3 together form a cyclic moiety in which one of Q2 and Q3 is a cyclic moiety selected from OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo or a group R5 as here in below defined for R2 and the other of Q2 and Q3 is a cyclic moiety selected from C1-2 alkylene, C1-2 alkenylene and OC1 alkylene optionally substituted by oxo; R6a and R6b are each H or a cyclic moiety as defined above; and Q1 is selected from H, R1 and R2 and a cyclic moiety as defined above; and R1-4 are H or substituenType: ApplicationFiled: February 15, 2013Publication date: February 19, 2015Inventors: Shailesh Mistry, Etíenne Daras, Christophe Fromont, Gopal Jadhav, Peter Martin Fischer, Barrie Kellam, Stephen John Hill, Jillian Glenda Baker
-
Publication number: 20150045423Abstract: The present invention relates to new compounds which are inter alia derivable from hops for use in the treatment of (for treating)/prevention or healing of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, in particular a disease which is associated with or characterized by degeneration and/or a destruction of cartilage (and/or for the prevention of aggrecan loss). Food products comprising these compounds for use in the treatment (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, in particular a disease which is associated with or characterized by degeneration and/or a destruction of cartilage, are also envisaged.Type: ApplicationFiled: August 22, 2014Publication date: February 12, 2015Inventors: Peter Prehm, Dennis Stracke
-
Publication number: 20150045358Abstract: A pharmaceutical composition for treating disorders associated with insulin resistance is disclosed, and the composition comprises at least one inhibitor which is an effective agent to suppress endothelin-1-stimulated resistin gene expression through decreasing the endothelin-1-stimulated phosphorylation of proteins downstream of endothelin type A receptor, wherein the downstream signaling molecules comprise ERK1/2, JNKs, AKT, and STAT3 proteins, and wherein the inhibitor is selected from at least one antagonist of the endothelin type A receptor or downstream signaling proteins.Type: ApplicationFiled: May 21, 2013Publication date: February 12, 2015Inventors: Yung-hsi KAO, Ya-chu Tang, Hsin-huei Chang, Hui-chen Ku
-
Patent number: 8952169Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: GrantFiled: May 21, 2013Date of Patent: February 10, 2015Assignees: Xenon Pharmaceuticals Inc., Genentech, Inc.Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
-
Patent number: 8952055Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: GrantFiled: February 2, 2009Date of Patent: February 10, 2015Assignee: Protectea, Ltd.Inventors: Kunihiro Kaihatsu, Shuichi Mori, Tomo Daidoji, Nobuo Kato, Shinya Miyake